Brind.
  1. Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).
  2. Novartis gains exclusive rights to develop ARO-SNCA through a collaboration that validates Arrowhead's TRiM technology.

Novartis entered a licensing deal with Arrowhead Pharmaceuticals to develop a treatment for Parkinson’s Disease.

1 report, 1 independent Updated Sep 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Novartis entered a licensing deal with Arrowhead Pharmaceuticals to develop a treatment for Parkinson’s Disease.

Who's involved

What this event is mainly about
Arrowhead PharmaceuticalsNovartis

Keep exploring

Part of

Novartis gains exclusive rights to develop ARO-SNCA through a collaboration that validates Arrowhead's TRiM technology. All 1 developments

Within Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • ZacksNVS Inks a Licensing Deal With Arrowhead for siRNA Therapy Novartis (NVS) has entered into a licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (ARWR) for the latter’s ARO-SNC